![Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET - Journal of Biological Chemistry Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET - Journal of Biological Chemistry](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9846c590-8c8a-401f-824f-0feb80af71cd/gr1_lrg.jpg)
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET - Journal of Biological Chemistry
![Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance | SpringerLink Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs43440-020-00131-0/MediaObjects/43440_2020_131_Fig1_HTML.png)
Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance | SpringerLink
![Figure 1 | Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer Figure 1 | Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer](https://static-01.hindawi.com/articles/bmri/volume-2011/165214/figures/165214.fig.001.jpg)
Figure 1 | Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer
![Epidermal growth factor receptor in relation to tumor development: EGFR‐targeted anticancer therapy - Okamoto - 2010 - The FEBS Journal - Wiley Online Library Epidermal growth factor receptor in relation to tumor development: EGFR‐targeted anticancer therapy - Okamoto - 2010 - The FEBS Journal - Wiley Online Library](https://febs.onlinelibrary.wiley.com/cms/asset/60a736f7-2867-4f80-8d1d-17c63bb7a9ff/febs_7449_f2.gif)
Epidermal growth factor receptor in relation to tumor development: EGFR‐targeted anticancer therapy - Okamoto - 2010 - The FEBS Journal - Wiley Online Library
![Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma](https://www.e-trd.org/upload//thumbnails/trd-79-248-g001.jpg)
Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
![Cancers | Free Full-Text | Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance | HTML Cancers | Free Full-Text | Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance | HTML](https://www.mdpi.com/cancers/cancers-11-00923/article_deploy/html/images/cancers-11-00923-g001.png)
Cancers | Free Full-Text | Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance | HTML
![Frontiers | EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies | Oncology Frontiers | EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies | Oncology](https://www.frontiersin.org/files/Articles/481731/fonc-09-01044-HTML/image_m/fonc-09-01044-g001.jpg)
Frontiers | EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies | Oncology
![Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review) Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)](https://www.spandidos-publications.com/article_images/ijo/59/5/IJO-59-05-05270-g03.jpg)
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)
![Clinical development of targeted and immune based anti-cancer therapies | Journal of Experimental & Clinical Cancer Research | Full Text Clinical development of targeted and immune based anti-cancer therapies | Journal of Experimental & Clinical Cancer Research | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13046-019-1094-2/MediaObjects/13046_2019_1094_Fig1_HTML.png)
Clinical development of targeted and immune based anti-cancer therapies | Journal of Experimental & Clinical Cancer Research | Full Text
![The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer | European Respiratory Society The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer | European Respiratory Society](https://err.ersjournals.com/content/errev/19/117/186/F1.large.jpg)
The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer | European Respiratory Society
![Predicting the Molecular Mechanism of EGFR Domain II Dimer Binding Interface by Machine Learning to Identify Potent Small Molecule Inhibitor for Treatment of Cancer - Journal of Pharmaceutical Sciences Predicting the Molecular Mechanism of EGFR Domain II Dimer Binding Interface by Machine Learning to Identify Potent Small Molecule Inhibitor for Treatment of Cancer - Journal of Pharmaceutical Sciences](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f0e6b0b2-5cef-4675-91d5-565e0f3e2637/gr1_lrg.jpg)
Predicting the Molecular Mechanism of EGFR Domain II Dimer Binding Interface by Machine Learning to Identify Potent Small Molecule Inhibitor for Treatment of Cancer - Journal of Pharmaceutical Sciences
![Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer | SpringerLink Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13238-021-00855-6/MediaObjects/13238_2021_855_Fig1_HTML.png)
Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer | SpringerLink
![Frontiers | The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells | Oncology Frontiers | The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells | Oncology](https://www.frontiersin.org/files/MyHome%20Article%20Library/506343/506343_Thumb_400.jpg)
Frontiers | The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells | Oncology
![An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor: Cell An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor: Cell](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c3c433e6-00f0-40c3-8262-f18962d1abe1/gr1_lrg.jpg)
An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor: Cell
![Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer | Experimental & Molecular Medicine Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer | Experimental & Molecular Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs12276-018-0202-2/MediaObjects/12276_2018_202_Fig1_HTML.png)
Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer | Experimental & Molecular Medicine
![The paradoxical functions of EGFR during breast cancer progression | Signal Transduction and Targeted Therapy The paradoxical functions of EGFR during breast cancer progression | Signal Transduction and Targeted Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsigtrans.2016.42/MediaObjects/41392_2017_Article_BFsigtrans201642_Fig1_HTML.jpg)